Cardiff Oncology Inc (CRDF)

Currency in USD
2.440
-0.130(-5.06%)
Closed·
After Hours
2.488+0.048(+1.98%)
·
CRDF Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
CRDF is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.4102.549
52 wk Range
2.0905.640
Key Statistics
Prev. Close
2.44
Open
2.5
Day's Range
2.41-2.549
52 wk Range
2.09-5.64
Volume
1.55M
Average Volume (3m)
1.82M
1-Year Change
8.93%
Book Value / Share
0.88
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CRDF Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
11.214
Upside
+359.60%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Cardiff Oncology Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Cardiff Oncology Inc Company Profile

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated ongoing or planned trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple negative breast cancer; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with SoC FOLFIRI and bevacizumab or SoC FOLFOX and bevacizumab for the first-line treatment of patients with RAS-mutated mCRC; TROV-054, a Phase 1b/2 open-label multi-center clinical trial of onvansertib in combination with SoC FOLFIRI and bevacizumab for the second-line treatment of patients with KRAS-mutated mCRC; and CRDF-001, a Phase 2 open-label multi-center clinical trial of onvansertib in combination with nanoliposomal irinotecan leucovorin, and fluorouracil for second line treatment of patients with mPDAC. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.

Cardiff Oncology Inc Earnings Call Summary for Q4/2024

  • Cardiff Oncology raised $40M, extending cash runway to Q1 2027 with $91.7M in reserves as of Dec 31, 2024
  • ONVANSERTIB showed promising results in metastatic colorectal cancer trials, positioning Cardiff as a potential market leader
  • Stock declined 8.97% in regular trading but rebounded 2.71% after hours, reflecting mixed market sentiment
  • Company plans to release additional clinical data in H1 2025 and engage with FDA on registrational strategy for ONVANSERTIB
  • CEO expressed optimism about ONVANSERTIB's potential to change treatment paradigm for RAS mutated MCRC patients
Last Updated: 27/02/2025, 23:24
Read Full Transcript

Compare CRDF to Peers and Sector

Metrics to compare
CRDF
Peers
Sector
Relationship
P/E Ratio
−3.2x−0.5x−0.5x
PEG Ratio
−0.69−0.010.00
Price/Book
2.8x2.0x2.6x
Price / LTM Sales
297.8x4.9x3.3x
Upside (Analyst Target)
309.8%70.3%43.5%
Fair Value Upside
Unlock18.1%6.9%Unlock

Analyst Ratings

7 Buy
1 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 11.214
(+359.60% Upside)

Earnings

Latest Release
Jul 29, 2025
EPS / Forecast
-0.21 / -0.19
Revenue / Forecast
120.00K / 96.43K
EPS Revisions
Last 90 days

CRDF Income Statement

People Also Watch

16.26
SRPT
-2.93%
0.561
WINT
+5.45%
38.47
BMNR
+15.53%
11.13
VERV
+0.27%
7.740
CAPR
+0.91%

FAQ

What Stock Exchange Does Cardiff Oncology Trade On?

Cardiff Oncology is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Cardiff Oncology?

The stock symbol for Cardiff Oncology is "CRDF."

What Is the Cardiff Oncology Market Cap?

As of today, Cardiff Oncology market cap is 162.32M.

What Is Cardiff Oncology's Earnings Per Share (TTM)?

The Cardiff Oncology EPS (TTM) is -0.87.

When Is the Next Cardiff Oncology Earnings Date?

Cardiff Oncology will release its next earnings report on 29 Oct 2025.

From a Technical Analysis Perspective, Is CRDF a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Cardiff Oncology Stock Split?

Cardiff Oncology has split 3 times.

How Many Employees Does Cardiff Oncology Have?

Cardiff Oncology has 33 employees.

What is the current trading status of Cardiff Oncology (CRDF)?

As of 07 Aug 2025, Cardiff Oncology (CRDF) is trading at a price of 2.44, with a previous close of 2.44. The stock has fluctuated within a day range of 2.41 to 2.55, while its 52-week range spans from 2.09 to 5.64.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.